Abstract
Peripheral T-cell lymphomas (PTCL) include a group of heterogeneous and rare lymphomas. The T-cell phenotype is an independent poor prognostic feature and these lymphomas have a lower cure rate with chemotherapy than with their B-cell counterparts. Retrospective studies suggest that high-dose therapy and autologous stem cell transplant (HDT-ASCT) may be feasible and effective for some patients in the salvage setting. However, many of these studies are biased by the inclusion of patients with ALK + anaplastic large cell lymphoma, an entity known to have a relatively positive prognosis with chemotherapy. Because PTCL have a generally poor prognosis, HDT-ASCT has been studied in first complete or partial remission for these patients as consolidation with favorable outcomes noted. However, there are currently no randomized trials that establish upfront HDT-ASCT as standard of care for patients with PTCL. Allogeneic transplantation is becoming more frequently used for these patients, as there is growing evidence for a graft-versus-lymphoma effect in these diseases and a growing acceptance for reduced intensity conditioning regimens. But, there continues to be limited data describing allogeneic transplantation for these diseases and, thus, the application of this modality of therapy for PTCL is still unclear.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11):3909–18
Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 13(1):140–149
Nakamura S, Suchi T, Koshikawa T, Suzuki H, Oyama A, Kojima M et al (1993) Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 72(5):1762–1772
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92(1):76–82
Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY et al (1997) Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15(6):2296–2301
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115(5):1026–1036
Horwitz SM (2008) Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 289–96
Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L et al (1997) Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 82(2):171–177
Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M et al (1989) Peripheral T-cell lymphoma. Cancer 63(1):158–163
Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 103(10):2091–2098
Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1(1):45–50
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7):2316–2323
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827–5834
Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B et al (2001) Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19(17):3766–3770
Kahl C, Leithauser M, Wolff D, Steiner B, Hartung G, Casper J et al (2002) Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 81(11):646–650
Song KW, Mollee P, Keating A, Crump M (2003) Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120(6):978–985
Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134(2):202–207
Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al (2003) High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14(12):1768–1775
Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O et al (2004) Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 33(4):405–410
Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40(5):443–450
Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG (2008) Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 14(7):741–747
Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH et al (2009) Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 15(1):118–125
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18(4):652–657
Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106–113
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79(1):32–38
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9):1533–1538
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958–963
Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T et al (2000) Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 25(1):111–113
Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM (2004) Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 34(6):521–525
Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, Yoshioka S et al (2006) Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108(1):382–389
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26(14):2264–2271
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G et al (2008) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26(2):218–224
Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al (2010) Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116(8):1369–1376
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al (2011) A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22:1608–1613
Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F et al (2012) Long term survival in patients with peripheral T cell lymphomas after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 53(6):1124–9
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22(11):2172–2176
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Goldberg, J.D., Casulo, C., Horwitz, S.M. (2013). The Role of Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphomas. In: Quesenberry, P., Castillo, J. (eds) Non-Hodgkin Lymphoma. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5851-7_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5851-7_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5850-0
Online ISBN: 978-1-4614-5851-7
eBook Packages: MedicineMedicine (R0)